Dr. Hermann Einsele Discusses the Results of the CARTITUDE-2 Study

What is the background of the study?

Cilta-cel (JNJ-68284528) is a chimeric antigen receptor T (CAR-T)-cell therapy with 2 BCMA-targeting, single-domain antibodies designed to confer high avidity binding. CARTITUDE-2 (NCT04133636) is a phase 2, multicohort, open-label study assessing the efficacy and safety of cilta-cel in patients (pts) with multiple myeloma in various clinical settings. Here, we describe the mitigation and management strategies implemented to identify and reduce the risk for neurologic adverse events (AEs) in Cohort A pts (progressive multiple myeloma after 1−3 prior lines of therapy).

In this video:

Dr. Hermann Einsele ( Universitätsklinikum Würzburg, Würzburg, Germany) discusses the results of CARTITUDE-2, which studies the incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel).

Conclusions:

Neurologic AEs were generally manageable in pts with MM following treatment with cilta-cel. With a median of 5.8 months of follow-up, there were no movement or neurocognitive disorders in pts from Cohort A. These results suggest that early detection and management of neurologic AEs can lead to better treatment outcomes. 

Clinical trial information: NCT04133636 (http://clinicaltrials.gov/show/NCT04133636)